Markets

MS biotech Forward Pharma files for a $200 million IPO

Forward Pharma A/S, a late-stage biotech developing treatments for multiple sclerosis and psoriasis, filed on Monday with the SEC to raise up to $200 million in an initial public offering.

The Copenhagen, Denmark-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol FWP. Forward Pharma A/S initially filed confidentially on April 9, 2014. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More